• Advanced Cell Technology Inc., of Marlborough, Mass., said the first subject in the third dosage cohort was injected with 150,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells in its European Phase I trial for Stargardt's macular dystrophy (SMD).